New Patient Database Enables Presentation Of Safety, Efficacy Data For Cryoablation

Endocare, Inc. (OTC Bulletin Board: ENDO), an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation, announced today promising results gathered from a new, extensive database of patients who have chosen cryoablation as their treatment for prostate cancer. J. Stephen Jones, M.D., Vice Chairman, Glickman Urological Institute of Cleveland Clinic, presented the results at the recent national meeting of the Society of Urologic Oncology.

Dr. Jones is the coordinating principle investigator of the database, called the Cryo On-Line Database (COLD). It is the largest database of cryoablation patients ever compiled and is based on an Institutional Review Board (IRB) approved protocol. The data in his presentation were based on the first 1,002 patients in the COLD registry who underwent cryoablation as a primary treatment for prostate cancer. The registry now contains data from more than 2,000 patients from across the U.S.

The average age of the patients in the Society of Urologic Oncology presentation was 70.4 years and they were followed for up to 10 years. The biochemical survival rate of all patients was 76.1 percent with 84 percent of low risk patients, 70.5 percent of moderate risk patients and 71.7 percent of high risk patients showing no biochemical (PSA) evidence of disease recurrence five years following treatment. The positive biopsy rate was 5.9 percent and the incontinence rates at six and 12 months were 4.5 percent and 2.0 percent, respectively.

"These are encouraging results and should help to continue to build the growing acceptance of cryoablation as a primary treatment for prostate cancer patients," Dr. Jones said. "Furthermore, while attending the meeting I found a significant growth in interest not only in cryoablation, but in the COLD registry. Many physicians I have spoken to who perform cryoablation expressed a desire to add their patient data to the registry. With any form of cancer therapy, data on large numbers of patients with at least five year survival information are crucial to widespread adoption. We are building a very important resource of information that greatly improves our understanding of cryotherapy outcomes, and now demonstrates that this minimally invasive treatment should be seriously considered as an option for increasing numbers of patients diagnosed with localized prostate cancer."

"We are confident that the COLD registry will prove to be a valuable tool to demonstrate the effectiveness of cryoablation," said Craig T. Davenport, Chairman, Chief Executive Officer and President of Endocare. "The data collection is ongoing and we expect to have 5,000 patients in the database in the near future. We believe this will offer us important clinical information including longer term follow-up of both morbidity and disease control and we look forward to presenting this information to the medical community."

About Endocare

Endocare, Inc. (http://www.endocare.com) is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver.

Statements contained in this release that are not historical facts are forward-looking statements that involve risks and uncertainties. Among the important factors which could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, those discussed in "Risk Factors" in the Company's Forms 10-K, Forms 10-Q, and other filings with the Securities and Exchange Commission. Such risk factors include, but are not limited to: uncertainly regarding the future availability of funds under the Company's common stock purchase agreement with Fusion Capital and credit facility with Silicon Valley Bank; the risk that the Company's sale of common stock to Fusion Capital may cause dilution; the risk that sales of common stock by Fusion Capital may cause the market price of the Company's common stock to decline; the risk that, even despite the Company's financing arrangements with Fusion Capital and Silicon Valley Bank, the Company's independent auditor may issue a qualified opinion, to the effect that there is a substantial doubt about the Company's ability to continue as a going concern; uncertainty regarding the Company's ability to reach and maintain profitability; risks relating to the loss of the Company's largest customer or the reduction, delay or cancellation of orders from this customer; the risk that the Company may be required to make state and local tax payments that exceed the Company's settlement estimates; uncertainty regarding the Company's re-listing on a national stock exchange; uncertainty regarding the effects of effectuating the Company's proposed reverse stock split, in particular the possibility that the market may react negatively to the Company's effectuation of a reverse stock split; uncertainty regarding market acceptance of the Company's products; uncertainty of product development and the associated risks related to clinical trials; uncertainty relating to third party reimbursement; uncertainty regarding the ability to convince health care professionals and third party payers of the medical and economic benefits of the Company's products; the Company's limited sales, marketing and manufacturing experience; uncertainty regarding the ability to attract and retain key personnel; uncertainty regarding the ability to secure and protect intellectual property rights relating to the Company's technology; the rapid pace of technological change in the Company's industry; fluctuations in the Company's order levels; and the risk that the Company may be subject to civil or criminal liability if the Company violates the terms of its settlements with the SEC and the DOJ. The actual results that the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. The Company undertakes no obligation to revise, or update publicly, any forward-looking statements for any reason.

Endocare, Inc.
http://www.endocare.com